AR088704A1 -
VAGINAL RING INCLUDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT FOR THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE OVARIC RESERVE IN WOMEN AND TO RELIEF SYMPTOMS ASSOCIATED WITH MENOPAUSE
- Google Patents
VAGINAL RING INCLUDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT FOR THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE OVARIC RESERVE IN WOMEN AND TO RELIEF SYMPTOMS ASSOCIATED WITH MENOPAUSE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CL2011003352Aexternal-prioritypatent/CL2011003352A1/en
Priority claimed from PCT/IB2011/056023external-prioritypatent/WO2013098592A1/en
Application filed by Univ Chile, Andromaco LabfiledCriticalUniv Chile
Publication of AR088704A1publicationCriticalpatent/AR088704A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Anillo vaginal de liberación sostenida que comprende como principio activo dehidroepiandrosterona (DHEA), dehidroepiandrosterona sulfato (DHEA-S) o una sal farmacéuticamente aceptable de éstos y, opcionalmente, un agente modulador de la liberación del principio activo, donde la cantidad del ingrediente activo se encuentra entre 1% a 32% en peso, en relación al peso total de la formulación y el agente modulador se selecciona entre: polivinilpirrolidona K-30, lactosa, celulosa microcristalina y lauril sulfato de sodio. El anillo vaginal de la presente es útil para aumentar la reserva ovárica en mujeres, para ser utilizado como medicamento en programas de reproducción asistida y para aliviar síntomas asociados a la menopausia, tales como síntomas de la atrofia vulvovaginal y disfunción sexual en mujeres post menopáusicas.Sustained-release vaginal ring comprising as active ingredient dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) or a pharmaceutically acceptable salt thereof and, optionally, an active ingredient release modulating agent, where the amount of the active ingredient is It is between 1% and 32% by weight, in relation to the total weight of the formulation and the modulating agent is selected from: polyvinylpyrrolidone K-30, lactose, microcrystalline cellulose and sodium lauryl sulfate. The vaginal ring of the present is useful to increase ovarian reserve in women, to be used as a medicine in assisted reproduction programs and to relieve symptoms associated with menopause, such as symptoms of vulvovaginal atrophy and sexual dysfunction in post menopausal women.
ARP120104974A2011-12-292012-12-26
VAGINAL RING INCLUDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT FOR THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE OVARIC RESERVE IN WOMEN AND TO RELIEF SYMPTOMS ASSOCIATED WITH MENOPAUSE
AR088704A1
(en)
Sustained-release vaginal ring comprising as active agent dehydroepiandrosterone, dehydroepiandrosterone sulfate or a salt thereof, and optionally a release agent modulating the active agent; and its use to increase ovarian reserve in women and to treat symptoms associated with menopause.
Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause
VAGINAL RING INCLUDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT FOR THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE OVARIC RESERVE IN WOMEN AND TO RELIEF SYMPTOMS ASSOCIATED WITH MENOPAUSE
VAGINAL RING THAT INCLUDES DHEA OR DHEA SULPHATE AND OPTIONALLY A MODULATING AGENT OF THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE THE OVARIAN RESERVE IN WOMEN AND TO RELIEVE SYMPTOMS ASSOCIATED WITH MENOPAUSE
OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
VAGINAL RING INCLUDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT FOR THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE OVARIC RESERVE IN WOMEN AND TO RELIEF SYMPTOMS ASSOCIATED WITH MENOPAUSE
Vaginal ring comprising dhea or dhea sulfate and optionally a modulating agent for the release of the active substance, useful to increase ovarian reserve in women and to relieve symptoms associated with menopause.
VAGINAL RING UNDERSTANDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT OF THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE OVARIC RESERVE IN WOMEN AND TO RELIEF SYMPTOMS ASSOCIATED WITH MENOPAUSE
VAGINAL RING THAT INCLUDES DHEA OR DHEA SULPHATE AND OPTIONALLY A MODULATING AGENT OF THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE THE OVARIAN RESERVE IN WOMEN AND TO RELIEVE SYMPTOMS ASSOCIATED WITH MENOPAUSE
VAGINAL RING INCLUDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT OF THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE OVARIC RESERVE IN WOMEN AND TO RELIEF SYMPTOMS ASSOCIATED WITH MENOPAUSE
Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women.
VAGINAL RING INCLUDING DHEA OR DHEA SULFATE AND OPTIONALLY A MODULATING AGENT OF THE RELEASE OF THE ACTIVE PRINCIPLE, USEFUL TO INCREASE THE OVARIC RESERVE IN WOMEN AND TO RELIEVE SYMPTOMS ASSOCIATED WITH MENOPAUSE
PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN ANTIANDROGEN AGENT, A SYNTHETIC ESTEROID STROGEN AGENT AND VITAMIN AGENTS, USEFUL FOR THE CONTROL AND TREATMENT OF LATE ACNE IN WOMEN
Sustained-release vaginal ring comprising as active agent dehydroepiandrosterone, dehydroepiandrosterone sulfate or a salt thereof, and optionally a release agent modulating the active agent; and its use to increase ovarian reserve in women and to treat symptoms associated with menopause.